<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Iopamidol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Iopamidol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Iopamidol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12006" href="/d/html/12006.html" rel="external">see "Iopamidol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F26524992"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Isovue-200, Isovue-250, Isovue-300, and Isovue-370 are not for intrathecal use.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F183910"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Isovue-200;</li>
<li>Isovue-250;</li>
<li>Isovue-300;</li>
<li>Isovue-370;</li>
<li>Isovue-M 200;</li>
<li>Isovue-M 300</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867234"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Isovue 200;</li>
<li>Isovue 300;</li>
<li>Isovue 370;</li>
<li>Isovue Multipack-300;</li>
<li>Isovue Multipack-370</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F183913"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Contrast Agent;</li>
<li>
                        Iodinated Contrast Media;</li>
<li>
                        Radiological/Contrast Media (Nonionic, Low Osmolality)</li></ul></div>
<div class="block doa drugH1Div" id="F7914544"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> General dosing guidelines are presented. Doses should be individualized and the lowest dose needed to obtain adequate visualization should be used. Patients should be well hydrated prior to and after administration. Refer to product information for detailed dosing and administration information.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="838306d1-0947-4e92-a587-bdef4ab26066">Intravascular imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravascular imaging:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Angiography:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cerebral arteriography: </i>Isovue-300: 8 to 12 mL by carotid puncture or transfemoral catheterization, with total multiple doses ranging to 90 mL</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Coronary arteriography and ventriculography:</i> Isovue-370: 2 to 10 mL for selective coronary artery injection; 25 to 50 mL for ventriculography or nonselective opacification of multiple coronary arteries following injection at the aortic root. Total dose for combined procedures has not exceeded 200 mL. EKG monitoring is essential during procedure.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Peripheral arteriography:</i> Isovue-300:</p>
<p style="text-indent:-2em;margin-left:8em;">Femoral artery or subclavian artery: 5 to 40 mL up to a total of 250 mL</p>
<p style="text-indent:-2em;margin-left:8em;">Aorta for a distal runoff: 25 to 50 mL up to a total of 250 mL</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Peripheral venography (phlebography):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Isovue-200: 25 to 150 mL per lower extremity. Combined total dose for multiple injections has not exceeded 350 mL.</p>
<p style="text-indent:-2em;margin-left:8em;">Isovue-300: 15 to 100 mL per lower extremity. Combined total dose for multiple injections should not exceed 230 mL</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Selective visceral arteriography and aortography:</i> Isovue-370: Up to 50 mL may be required for injection into the larger vessels, such as the aorta or celiac artery; doses up to 10 mL may be required for injection into the renal arteries. Combined total dose for multiple injections has not exceeded 225 mL.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Computed tomography: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CECT of the head:</i> IV: Imaging may be performed immediately after completion of administration.</p>
<p style="text-indent:-2em;margin-left:8em;">Isovue-250:130 to 240 mL; maximum: 240 mL</p>
<p style="text-indent:-2em;margin-left:8em;">Isovue-300: 100 to 200 mL; maximum: 200 mL</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CECT of the body:</i> IV by rapid infusion or bolus injection:</p>
<p style="text-indent:-2em;margin-left:8em;">Isovue-250: 130 to 240 mL; maximum: 240 mL</p>
<p style="text-indent:-2em;margin-left:8em;">Isovue-300: 100 to 200 mL; maximum: 200 mL</p>
<p style="text-indent:-2em;margin-left:8em;">Equivalent doses of Isovue-370 based on organically bound iodine content may also be used.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Urography, excretory:</b> Administer by rapid IV injection</p>
<p style="text-indent:-2em;margin-left:6em;">Isovue-250: 50 to 100 mL</p>
<p style="text-indent:-2em;margin-left:6em;">Isovue-300: 50 mL</p>
<p style="text-indent:0em;margin-left:4em;">Isovue-370: 40 mL</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a4f2afb-1259-4ba8-9710-5dcd1375aab0">Intrathecal imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Intrathecal imaging:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Computed tomographic cisternography:</b> Isovue-M 200: 4 to 6 mL via lumbar injection</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Myelography:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lumbar or thoracic myelogram:</i> Isovue-M 200: 10 to 15 mL</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cervical myelogram (via lumbar injection):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Isovue-M 200: 10 to 15 mL</p>
<p style="text-indent:-2em;margin-left:8em;">Isovue-M 300: 10 mL</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cervical myelogram (via lateral cervical injection):</i> Isovue-M 200: 10 mL</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Total columnar myelography:</i> Isovue-M 300: 10 mL</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990674"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in severe impairment, anuria, and in the setting of combined renal and hepatic disease.</p></div>
<div class="block doha drugH1Div" id="F50987938"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with combined hepatic and renal disease.</p></div>
<div class="block doe drugH1Div" id="F7914545"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F7976883"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> General dosing guidelines are presented. Doses should be individualized and the lowest dose needed to obtain adequate visualization should be used. Patients should be well hydrated prior to and after administration. Refer to product information for detailed dosing and administration information.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="838306d1-0947-4e92-a587-bdef4ab26066">Intravascular imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravascular imaging: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Angiocardiography:</b> Isovue-370: <b>Note:</b> May be performed by injection into a large peripheral vein or direct catheterization of the heart:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;2 years: Single injection: 10 to 15 mL; cumulative injection: 40 mL</p>
<p style="text-indent:-2em;margin-left:6em;">2 to 4 years: Single injection: 15 to 30 mL; cumulative injection: 50 mL</p>
<p style="text-indent:-2em;margin-left:6em;">5 to 9 years: Single injection: 15 to 30 mL; cumulative injection: 100 mL</p>
<p style="text-indent:-2em;margin-left:6em;">10 to 18 years: Single injection: 20 to 50 mL; cumulative injection: 125 mL</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Computed tomography:</b> IV:</p>
<p style="text-indent:-2em;margin-left:6em;">CECT of the head and body:</p>
<p style="text-indent:-2em;margin-left:8em;">Isovue-250: 1.2 to 3.6 mL/kg; maximum: 120 mL</p>
<p style="text-indent:-2em;margin-left:8em;">Isovue-300: 1 to 3 mL/kg; maximum: 100 mL</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Urography, excretory:</b> IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Isovue-250: 1.2 to 3.6 mL/kg; should not be necessary to exceed a total dose of 120 mL</p>
<p style="text-indent:-2em;margin-left:6em;">Isovue-300: 1 to 3 mL/kg; should not be necessary to exceed a total dose of 100 mL</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a4f2afb-1259-4ba8-9710-5dcd1375aab0">Intrathecal imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrathecal imaging:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Myelography:</b>
<i>Lumbar or thoracic myelogram:</i> Isovue-M 200:</p>
<p style="text-indent:-2em;margin-left:6em;">2 to 7 years: 7 to 9 mL</p>
<p style="text-indent:-2em;margin-left:6em;">8 to 12 years: 8 to 11 mL</p>
<p style="text-indent:-2em;margin-left:6em;">13 to 18 years: 10 to 12 mL</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113919"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in severe impairment, anuria, and in the setting of combined renal and hepatic disease.</p></div>
<div class="block dohp drugH1Div" id="F51113920"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with combined hepatic and renal disease.</p></div>
<div class="block adr drugH1Div" id="F7914490"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (≤16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (≤3%), bigeminy (≤1%), bradycardia (≤1%), chest pain (≤1%), circulatory shock (≤1%), cold extremity (≤1%), depression of ST segment on ECG (≤1%), extrasystoles (≤1%), flushing (≤2%), hypertension (≤1%), hypotension (≤1%), ischemic heart disease (≤1%), syncope (≤1%), tachycardia (≤1%), thrombophlebitis (≤1%), tingling of the arms (≤1%), transient ischemic attacks (≤1%), vasodepressor syncope (≤1%), ventricular fibrillation (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (≤1%), pruritus (≤1%), skin rash (≤1%), urticaria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (≤1%), diarrhea (≤1%), dysgeusia (≤1%), heartburn (≤1%), nausea (1% to 7%), vomiting (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized irritation (≤1%; cervicobrachial, lumbosacral, meningeal, radicular), pain at injection site (≤1%, including erythema at injection site, swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia (≤1%), burning sensation (1%), chills (≤1%), confusion (≤1%), dizziness (≤1%), facial grimace (≤1%), fatigue (≤1%), hallucination (≤1%), involuntary body movements (≤1%; including involuntary movements of limbs [legs]), irritability (≤1%), localized warm feeling (1%), malaise (≤1%), myasthenia (≤1%; including ocular muscle weakness), numbness (≤1%), pain (3%), paresthesia (≤1%), sciatica (≤1%), stress (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (≤1%), back pain (2%), back spasm (≤1%), lower extremity pain (1%), lower limb cramp (≤1%), musculoskeletal pain (≤1%), neck pain (1%; including neck stiffness)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (≤1%), nasal congestion (≤1%), pharyngeal edema (≤1%), pulmonary edema (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: ECG changes (including prolonged QT interval on ECG, increased R-R wave, T-wave amplitude), increased left ventricular end-diastolic pressure, systolic hypotension</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial spasm, atrioventricular block, cardiac arrhythmia, cardiac decompensation, chest tightness, facial edema, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pallor</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypothyroidism (premature infants, infants, and children ≤3 years with underlying medical conditions may be more vulnerable; FDA Safety Alert March 30, 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, retching (severe)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Absent reflexes, agitation, amnesia (temporary), anxiety, apprehension, aseptic meningitis, asterixis, bacterial meningitis, choking sensation (severe), coma, depersonalization, depression, disorientation, dysphasia, genitourinary pain, Guillain-Barre syndrome, hyperesthesia, hyperreflexia, hypertonia, myoclonus, paralysis, peripheral neuropathy (including peripheral sensory neuropathy, peripheral motor neuropathy, nerve root disorder, myelitis, sixth nerve palsy, cauda equina syndrome), restlessness, seizure, speech disturbance (including echolalia), spinal myoclonus, stupor, transient organic psychosis, trigeminal neuralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Fasciculations, muscle cramps, muscle hypotonia, muscle spasm, muscle spasticity, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, cortical blindness, eye pruritus, lacrimation, periorbital edema</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory disturbance (including echoacousia), hearing loss, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, asthma, increased cough, laryngeal edema, rhinitis, sneezing</p></div>
<div class="block coi drugH1Div" id="F183905"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Intravenous: There are no contraindications listed in the manufacturers labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal: Concurrent intrathecal corticosteroid administration; immediate repeat myelography in the event of technical failure (potential for overdose); significant local or systemic infection where bacteremia is likely (myelography only).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to iopamidol or any component of the formulation; significant renal and/or hepatic impairment; direct intracisternal administration or gravitational displacement of a concentrated bolus of iopamidol into the intracranial subarachnoid spaces.</p></div>
<div class="block war drugH1Div" id="F7914489"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contrast-induced hypersensitivity reactions: Adverse reactions (including delayed reactions) to iodine-containing contrast media have occurred. Most cases are minor; however, serious and life-threatening reactions may occur without warning and often resemble allergic-type reactions. Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to several weeks after administration; reaction severity may increase and time to onset may decrease with repeat administration; avoid use in patients with a history of severe cutaneous adverse reactions. Patients with a history of bronchial asthma, allergy (including food allergy), family history of allergy, or prior allergy or hypersensitivity to contrast agents are at a higher risk for allergic reaction. Obtain allergy and hypersensitivity history prior to administration. Pretesting for allergic reaction may not reliably predict potential for reaction. Premedication with antihistamines and corticosteroids should be considered in patients at risk for allergic reaction (strong allergy history, prior contrast media reaction, or positive pretest) to reduce the incidence and severity of reactions. Monitor closely for 30 to 60 minutes after administration of the contrast media. A higher incidence of adverse reactions was reported in patients also receiving general anesthesia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Contrast-associated acute kidney injury: Acute kidney injury, including renal failure, may occur following administration of iodinated contrast media. Risk factors include patients with preexisting renal disease, advanced age, advanced vascular disease, heart failure, dehydration, diabetes, concomitant use of nephrotoxic agents or diuretics, multiple myeloma, or large doses or multiple doses of iodinated contrast media. Adequately hydrate patients prior to and following administration to minimize the risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: May be a vesicant; ensure proper needle/catheter/line placement prior to and during administration. Monitor infusion site. Avoid infiltration. Extravasation may result in tissue necrosis and/or inflammation, particularly in patients with severe arterial or venous disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Avoid in patients with history of epilepsy unless medically justified; focal and generalized motor seizures have been reported after intrathecal use; antiseizure therapy should be continued. Premedication with barbiturates or phenytoin should be considered in patients with a history of seizure activity not currently on antiseizure therapy. CNS-acting agents, primarily those which lower seizure threshold (eg, phenothiazines, MAO inhibitors, tricyclic antidepressants, CNS stimulants), may be withheld 48 hours pre- and 24 hours post-intrathecal contrast administration, based on consideration of the potential risks and benefits.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: Serious, rarely fatal, thromboembolic events causing MI and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Ionic iodinated contrast media may inhibit blood coagulation (more than nonionic contrast media). Use meticulous intravascular administration techniques during angiographic procedures. Clotting has been reported when in vitro blood remains in contact with syringes containing nonionic contrast media; use of plastic syringes in place of glass syringes has been reported to decrease, but not eliminate, the likelihood of in vitro clotting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease, especially when combined with renal impairment; severe, life-threatening, and fatal cardiovascular reactions have occurred. Observe patients with heart failure for several hours following the procedure to detect delayed hemodynamic disturbances, which may be associated with a transitory increase in the circulating osmotic load. Perform selective coronary angiography only if the anticipated benefit outweighs potential risks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes; these patients may have altered renal blood flow, increasing the risk of nephrotoxicity. Preparatory dehydration may contribute to acute renal failure in patients with diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with combined renal and hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Thyroid storm following intravascular administration of iodinated contrast media has occurred in patients with hyperthyroidism or with an autonomously functioning thyroid nodule.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may worsen myasthenia gravis (MG); use with caution and monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected). Minimize the amount of contrast agent used (for intravascular administration) and monitor blood pressure closely throughout procedure. Therapy for treatment of hypertensive crisis should be readily available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment, combined renal and hepatic impairment, or anuria, especially if large doses or repeat doses are needed. Preparatory dehydration may contribute to acute renal failure in patients with preexisting renal impairment. Acute renal failure has been reported in patients with preexisting renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sickle cell disease: Use with caution in sickle cell disease; may promote sickling in patients homozygous for sickle cell disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients. Preparatory dehydration may contribute to acute renal failure in elderly patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatrics: Pediatric patients at higher risk of experiencing any adverse events during contrast medium administration may include those having asthma, sensitivity to medication or allergens, cyanotic heart disease, heart failure, serum creatinine &gt;1.5 mg/dL, or those &lt;12 months. Thyroid dysfunction, including transient thyroid suppression or hypothyroidism, has been reported in pediatric patients 0 to 3 years of age following single exposure and multiple exposures to iodinated contrast media; risk increases with younger age, very low birth weight, prematurity, underlying medical conditions affecting thyroid function, neonatal or pediatric intensive care admission, and congenital cardiac conditions (may be greatest risk due to requiring higher doses during invasive cardiac procedures).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:2em;">• Appropriate use: Isovue-200, Isovue-250, Isovue-300, and Isovue-370 are not for intrathecal use. Serious adverse reactions (eg, acute renal failure, arachnoiditis, cardiac arrest, cerebral hemorrhage, coma, seizures, brain edema, hyperthermia, paralysis, rhabdomyolysis, death) have been reported due to inadvertent intrathecal administration of iodinated contrast agents not indicated for intrathecal use.</p>
<p style="text-indent:-2em;margin-left:2em;">• Appropriate use: <i>Intrathecal administration (Isovue-M 200 and Isovue-M 300 only): </i> Direct intracisternal or ventricular administration for standard radiography (without computerized tomographic enhancement) is not recommended. Avoid inadvertent intracranial administration of large dose or concentrated bolus of contrast medium; avoid rapid dispersion of medium, which could lead to inadvertent rise in intracranial levels (as may occur with active patient movement). If such intracranial entry of the medium occurs, prophylactic antiseizure treatment with diazepam or barbiturates orally for 24 to 48 hours should be considered. Use intrathecal administration with caution in patients with multiple sclerosis, increased intracranial pressure or suspicion of intracranial tumor, abscess, hematoma, chronic alcoholism, and the elderly. If frankly bloody cerebrospinal fluid is observed, the anticipated benefit versus the potential risks should be considered prior to myelography.</p>
<p style="text-indent:-2em;margin-left:2em;">• Appropriate use: <i>Intravascular administration:</i> In angiographic procedures, during catheter manipulations and contrast medium injection, a possibility of dislodging plaques or damaging (or perforating) vessel walls exists. Ensure proper catheter placement with test injections. In contrast-enhanced computerized tomography (CECT), contrast may obscure some lesions previously seen on unenhanced CT scans.</p>
<p style="text-indent:-2em;margin-left:2em;">• Appropriate use: Coronary arteriography: Use with caution in patients with chronic pulmonary emphysema.</p>
<p style="text-indent:-2em;margin-left:2em;">• Appropriate use: Venography: Use with caution in patients with suspected thrombosis, phlebitis, severe ischemic disease, local infection, or a totally obstructed venous system. Fluoroscopy is recommended, especially in patients with severe arterial or venous disease.</p>
<p style="text-indent:-2em;margin-left:2em;">• Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>
<div class="block foc drugH1Div" id="F183902"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue-M 200: 41% (10 mL, 20 mL [DSC]) [contains edetate (edta) calcium disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue-M 300: 61% (15 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 41% (10 mL, 20 mL); 61% (15 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue-200: 41% (50 mL [DSC], 200 mL) [contains edetate (edta) calcium disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue-250: 51% (50 mL [DSC], 100 mL, 150 mL [DSC], 200 mL [DSC]) [contains edetate (edta) calcium disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue-300: 61% (30 mL, 50 mL, 75 mL [DSC], 100 mL, 150 mL, 200 mL, 500 mL) [contains edetate (edta) calcium disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue-370: 76% (50 mL, 75 mL, 100 mL, 125 mL, 150 mL, 200 mL, 500 mL) [contains edetate (edta) calcium disodium]</p></div>
<div class="block geq drugH1Div" id="F183898"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323205"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Iopamidol Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">41% (per mL): $6.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">61% (per mL): $5.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Isovue-200 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">41% (per mL): $0.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Isovue-250 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">51% (per mL): $0.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Isovue-300 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">61% (per mL): $0.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Isovue-370 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">76% (per mL): $0.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Isovue-M 200 Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">41% (per mL): $7.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Isovue-M 300 Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">61% (per mL): $6.87</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867235"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue 370: 370 mg/mL (50 mL, 100 mL, 150 mL, 200 mL) [contains edetate (edta) calcium disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue 200: 41% (20 mL, 50 mL, 100 mL, 200 mL) [contains edetate (edta) calcium disodium]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue 300: 61% (15 mL, 50 mL, 100 mL, 150 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue Multipack-300: 61% (500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isovue Multipack-370: 76% (500 mL)</p></div>
<div class="block adm drugH1Div" id="F7914546"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Precautions should be taken to ensure products intended for IV administration are not administered intrathecally.</b> Patients should be well hydrated prior to and following procedure. Premedication with antihistamines or corticosteroids may be considered in some patients to minimize the potential for allergic reactions. Solutions should be at body temperature prior to administration. In angiography, use meticulous intravascular administration technique to minimize thrombotic events including use of plastic syringes, frequent catheter flushing, and close attention to catheter and guidewire manipulation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">May be a vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Intrathecal:</b> Administer slowly over 1 to 2 minutes to avoid excessive mixing with CSF through a lumbar needle under fluoroscopic control. If repeat examination is needed, an interval of at least 48 hours should be allowed; whenever possible 5 to 7 days is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.2'])">Ref</a></span>). Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.2'])">Ref</a></span>); other sources suggest its utility in extravasation management for inoperable cases with compartment syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If using hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Dose varies based on the size of infiltration; inject a total of 5 to 250 units (~100 mL contrast reabsorbed per 15 units of hyaluronidase) around the site of extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613072"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Patients should be well hydrated prior to and following procedure. Premedication with antihistamines or corticosteroids may be considered in some patients to minimize the potential for allergic reactions. Solutions should be at body temperature prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: <b>Precautions should be taken to ensure products intended for IV administration are not administered intrathecally.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Angiocardiography:</i> Isovue 370: Administer by IV injection into a large peripheral vein or by direct catheterization of the heart</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urography, excretory:</i> Isovue 250, Isovue 300: Administer by rapid IV injection</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Computed tomography (head and body): </i>Isovue 250, Isovue 300: Administer by rapid IV infusion or bolus injection</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>). Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>); other sources suggest its utility in extravasation management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12386778','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12386778','lexi-content-ref-24420913'])">Ref</a></span>) (see Management of Drug Extravasations for more details).</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal: Isovue M 200:<b> Precautions should be taken to ensure products intended for IV administration are not administered intrathecally.</b> Administer slowly over 1 to 2 minutes to avoid excessive mixing with CSF through a lumbar needle under fluoroscopic control. If repeat examination is needed, an interval of at least 48 hours should be allowed; whenever possible 5 to 7 days is recommended.</p></div>
<div class="block use drugH1Div" id="F183903"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Angiography:</b>
<i>Isovue</i>: Diagnostic agent for angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Computed tomography: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Isovue:</i> Diagnostic agent for adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Isovue-M: </i> Diagnostic agent for CECT cisternography and ventriculography in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelography:</b>
<i>Isovue-M:</i> Diagnostic agent for myelography (lumbar, thoracic, cervical, total columnar) in adults; diagnostic agent for myelography (lumbar, thoracic) in children &gt;2 years.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urography:</b>
<i>Isovue:</i> Diagnostic agent for adult and pediatric excretory urography.</p></div>
<div class="block mst drugH1Div" id="F56381758"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299531"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221095"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the nephrotoxic effect of Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Iodinated Contrast Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue iodinated contrast agents before sodium iodide I-131 administration, and avoid concurrent use. Stop water soluble agents 2 months before, and stop lipophilic agents 6 months before, sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F183907"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Iopamidol crosses the placenta and can be detected in the newborn gut at birth (Fitzpatrick 2011; Huang 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Thyroid dysfunction in the neonate has not been reported (Atwell 2011). However, due to theoretical concerns that exposure to free iodide may adversely affect the fetus, use should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 723 2017; ACR 2018).</p></div>
<div class="block brc drugH1Div" id="F7914488"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Iodinated contrast media may be present in breast milk (ACOG 723 2017; ACR 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant's GI tract, breastfeeding may be continued without interruption after use (ACOG 723 2017; ACR 2018). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding may express and discard milk from both breasts during a period of 12 to 24 hours after the administration of contrast media. They can pump and store milk prior to the procedure then bottle feed using the stored milk during this time (ACR 2018). The manufacturer recommends that caution be exercised when administering iopamidol to breastfeeding women.</p></div>
<div class="block dic drugH1Div" id="F9836149"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F25314416"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">ECG (during coronary arteriography and ventriculography procedures); hydration; signs/symptoms of hypersensitivity during and for at least 30 to 60 minutes following procedure; renal function; monitor infusion site for extravasation during IV administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric patients 0 to 3 years of age: Individualize thyroid function monitoring based on underlying risk factors, especially in term and preterm neonates.</p></div>
<div class="block pha drugH1Div" id="F7914497"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Opacification of vessels and anatomical structures in the path of flow of the contrast media which allows for radiographic visualization. </p></div>
<div class="block phk drugH1Div" id="F7914499"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: None</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: ~2 hours; prolonged in renal impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80% to 90% unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F183908"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Opacrile</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Jopamiro</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Iopamiron</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Radiomiron</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Iopamiron</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Solutrast</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Iopamiron</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Iopamed | Iopamiron</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Iopamigita</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro | Scanlux</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Gastromiro</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro | Iopasen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bystage | Hisidol | Iopamiron | Ovaniron</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lesopam 370</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Iopamigita | Iopamiro</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Iopamiron</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Iopamed | Iopamiron</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Iopamiron | Scanlux</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro | Pamiray</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Iopamiro</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Tomoskan</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Iopamiron</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Iopamiron</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28937575">
<a name="28937575"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. Erratum in: <i>Obstet Gynecol</i>. 2018;132(3):786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/28937575/pubmed" id="28937575" target="_blank">28937575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. Version 10.3. 2018. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Accessed October 17, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.2">
<a name="ACR.2"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published 2023. Accessed May 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18562757">
<a name="18562757"></a>Atwell TD, Lteif AN, Brown DL, McCann M, Townsend JE, Leroy AJ. Neonatal thyroid function after administration of IV iodinated contrast agent to 21 pregnant patients. <i>AJR Am J Roentgenol</i>. 2008;191(1):268-271. doi: 10.2214/AJR.07.3336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/18562757/pubmed" id="18562757" target="_blank">18562757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12386778">
<a name="12386778"></a>Bellin MF, Jakobsen JA, Tomassin I, et al; Contrast Media Safety Committee Of The European Society Of Urogenital Radiology. Contrast medium extravasation injury: guidelines for prevention and management. <i>Eur Radiol</i>. 2002;12(11):2807-2812. doi: 10.1007/s00330-002-1630-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/12386778/pubmed" id="12386778" target="_blank">12386778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21072507">
<a name="21072507"></a>Fitzpatrick J, Speakman J, Kapfer SA, Holston AM. Transplacental passage of the non-ionic contrast agent iopamidol in twins. <i>Pediatr Radiol</i>. 2011;41(4):534-536. doi: 10.1007/s00247-010-1888-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/21072507/pubmed" id="21072507" target="_blank">21072507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24534573">
<a name="24534573"></a>Huang TK, Reese J, Weitkamp JH, Stancombe BB. Congenital radiocontrast agent in the neonatal gut. <i>J Pediatr</i>. 2014;164(5):1236-1236.e1. doi: 10.1016/j.jpeds.2014.01.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/24534573/pubmed" id="24534573" target="_blank">24534573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isovue.1">
<a name="Isovue.1"></a>Isovue, Isovue-200, Isovue-300, Isovue-370, Isovue Multipack-300, Isovue Multipack-370 (iopamidol) [product monograph]. Montreal, Quebec, Canada: Bracco Imaging Canada; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isovue.2">
<a name="Isovue.2"></a>Isovue-200, Isovue-250, Isovue-300, Isovue-370 (iopamidol) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics; April 2023.</div>
</li>
<li>
<div class="reference">
                  Isovue-300 Bulk Package, Isovue-370 Bulk Package (iopamidol) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isovue.3">
<a name="Isovue.3"></a>Isovue-M 200, Isovue-M 300 (iopamidol) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy.</i> 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy.</i> 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8932 Version 207.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
